A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

ClinicalTrials.gov ID: NCT07456033

Public ClinicalTrials.gov record NCT07456033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Study identification

NCT ID: NCT07456033
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 456 participants

Conditions and interventions

Conditions

Asthma

Interventions

Depemokimab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 12, 2026
Primary completion: Sep 22, 2030
Completion: Sep 22, 2030
Last update posted: Aug 16, 2026

2026 – 2030

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
GSK Investigational Site	Little Rock	Arkansas	72205	Recruiting
GSK Investigational Site	Newport Beach	California	92663	Recruiting
GSK Investigational Site	Aurora	Colorado	80012	Recruiting
GSK Investigational Site	Aventura	Florida	33180	Recruiting
GSK Investigational Site	Kissimmee	Florida	34746	Recruiting
GSK Investigational Site	Lake Worth	Florida	33460	Recruiting
GSK Investigational Site	Miami	Florida	33135	Recruiting
GSK Investigational Site	Miami	Florida	33144	Recruiting
GSK Investigational Site	Miami	Florida	33173	Recruiting
GSK Investigational Site	Shreveport	Louisiana	71105	Recruiting
GSK Investigational Site	Oklahoma City	Oklahoma	73112	Recruiting
GSK Investigational Site	DuBois	Pennsylvania	15801	Recruiting
GSK Investigational Site	Wyomissing	Pennsylvania	19610	Recruiting
GSK Investigational Site	Rapid City	South Dakota	57702	Recruiting
GSK Investigational Site	San Antonio	Texas	78229	Recruiting
GSK Investigational Site	Burke	Virginia	22015	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07456033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 16, 2026 · Synced Sep 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07456033 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →